Yoskowitz Marc J 4

What Happened

• Marc J. Yoskowitz, a director of Keenova Therapeutics plc, had restricted stock units (RSUs) settle on June 2, 2026. The filing reports 3,579 shares issued on conversion/exercise of derivative awards. Of those, 825 shares were withheld to satisfy tax withholding obligations and 2,930 RSUs were forfeited/returned to the issuer under an agreement. The filing shows no cash proceeds (prices reported as N/A or $0.00).

Key Details

• Transaction date(s): June 2, 2026; Form filed June 4, 2026 (Accession 0001104659-26-070516).
• Reported transactions: Conversion/exercise (3,579 shares acquired), tax withholding (825 shares withheld/disposed), forfeiture/disposition to issuer (2,930 RSUs disposed), and a related $0.00 disposition entry.
• Prices/values: Reported as N/A or $0.00; no cash sale proceeds disclosed.
• Shares owned after transaction: Not specified in this Form 4.
• Notable footnotes: RSUs settled 1-for-1 into ordinary shares (F1); withholding amount based on a percentage and not market value because shares are not listed (F2); 2,930 RSUs forfeited in exchange for a payment from the issuer to help satisfy tax obligations related to scheduled vesting (F3); vesting schedule of these RSUs noted (F4,F5).
• Filing note: This Form 4 also serves as the issuer notice required under Part V of the Companies Act 2014.

Context

• These transactions reflect RSU settlement and internal adjustments (tax withholding and a contractual forfeiture), not an open-market sale or purchase. Because shares were withheld and RSUs forfeited as part of settlement/tax arrangements, the filing does not signal a cash sale by the director and no market proceeds are reported.